AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06241235
Drug: ZG005 Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Trial: NCT04443868
Drug: Nitric Oxide-Releasing Drug
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal Spray + Nasal Irrigation
Trial: NCT05648266
Drug: Continous SAPB (Ropivacain)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
Trial: NCT06256588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as an IV infusion
Trial: NCT04508166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
Trial: NCT05022186
Drug: Homotaurine
RxNorm normalized name: N-Acetylhomotaurine
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will use it with specific instructions and they will be monitored at least one time in a month
Trial: NCT06379165
Drug: Meloxicam Nanocrystal Injection
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg (1 mL), once daily, by intravenous infusion
Trial: NCT06379165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL Placebo, once daily, by intravenous infusion
Trial: NCT06055179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
Trial: NCT05176964
Drug: CAPOX chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
Trial: NCT04778644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gel capsule placebo
Trial: NCT04838639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subjects per cohort will take a matched placebo.
Trial: NCT05085327
Drug: ChapStick Lip Moisturizer Original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT05085327
Drug: ChapStick Lip Moisturizer Mint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT05085327
Drug: SPF Standard Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Trial: NCT04268706
Drug: CD30.CAR-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
Trial: NCT05219357
Drug: Usual-Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
Trial: NCT05627791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
Trial: NCT06462053
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xeloda
Trial: NCT05687253
Drug: BX1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV BX1000
Trial: NCT05164393
Drug: AVX001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel treatment for once daily application
Trial: NCT05712941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Trial: NCT06444997
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
Trial: NCT04796714
Drug: Double antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
Trial: NCT05077930
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
Trial: NCT05815004
Drug: Enzyme Replacement Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A hydrolytic lysosomal glucocerebrosidase-specific enzyme
Trial: NCT05457582
Drug: Placebo plus high-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
Trial: NCT05457582
Drug: PCSK 9 Inhibitor plus high-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
Trial: NCT00000801
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000801
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05845645
Drug: UCB0599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
Trial: NCT05555303
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In addition to the all-oral RR-TB treatment, add two intramuscular doses each consisting of 30 mg amikacin/kg, a first dose on day 1 and a second dose on day 4, all in the first week of treatment.~The amikacin solution will be admixed with a lidocaine solution in the syringe before administration.
Trial: NCT05625698
Drug: MagTrace only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see information in arm descriptions
Trial: NCT05620316
Drug: BOTOX® Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point
Trial: NCT04738318
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
Trial: NCT05249335
Drug: OST
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive Orafang for colonoscopy
Trial: NCT05249335
Drug: 2L-PEG/Asc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive 2L-PEG/Asc for colonoscopy
Trial: NCT06236191
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin
Trial: NCT04742907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo product
Trial: NCT04743115
Drug: BS HH 002.SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL
Trial: NCT06268652
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m² , PO, bid, days1-14, q3w
Trial: NCT05905172
Drug: The placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
Trial: NCT06353165
Drug: Colgate Dental Cream
RxNorm normalized name: Colgate Dental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: product containing 0.76% sodium monofluorophosphate
Trial: NCT05118750
Drug: ALTO-300 oral (PO) tablet
RxNorm normalized name: Altoprev Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet daily
Trial: NCT05017168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching CT-P63
Trial: NCT05853341
Drug: RID-TDS 13.3 mg/24 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
Trial: NCT05853341
Drug: Exelon® 13.3 mg/24 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Trial: NCT06166056
Drug: CHF6333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6333 Part I SAD; CHF6333 Part II MD.
Trial: NCT06166056
Drug: CHF6333 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Part I SAD; Placebo Part II MD.
Trial: NCT05036174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to diphenhydramine 5% ointment
Trial: NCT04839510
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT00000895
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04838496
Drug: FOLFOXIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age.
Trial: NCT05208242
Drug: hyperoncotic human albumin solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% human albumin solution (presented in 100ml glass bottles)
Trial: NCT05208242
Drug: Buffered crystalloid solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered crystalloids solutions for all intravenous fluid therapy
Trial: NCT05738135
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 50 ml normal saline over 30 minutes.
Trial: NCT06081049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT05598580
Drug: Adenosylmethionine
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
Trial: NCT05103423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple IV infusions of Placebo Injection diluted in sodium chloride
Trial: NCT04222257
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
Trial: NCT04222257
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
Trial: NCT05222087
Drug: SoC systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
Trial: NCT04960644
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
Trial: NCT04360681
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05912387
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg tablet once daily by mouth
Trial: NCT00005920
Drug: L-743,872
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04784897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion
Trial: NCT04784897
Drug: Standard of Care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC therapies for COVID-19
Trial: NCT06143358
Drug: Qingkepingchuan Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingkepingchuan Granules,Take it three times a day with water after meals.
Trial: NCT06417268
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
Trial: NCT06417268
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P atients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
Trial: NCT04989660
Drug: 6% aqueous phenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.
Trial: NCT04989660
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
Trial: NCT04300985
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
Trial: NCT05815797
Drug: SDD formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD formula consists of 23 herbal medicines
Trial: NCT05815797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05637567
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg per os once daily
Trial: NCT05637567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill per os once daily
Trial: NCT04836806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
Trial: NCT02021474
Drug: AGX-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT02021474
Drug: Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05089526
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Trial: NCT05467319
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 0.9% normal saline (w/v) by intravenous infusion
Trial: NCT05981157
Drug: Anrotinib plus Tirelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
Trial: NCT02930811
Drug: Placebo oral morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months
Trial: NCT06488625
Drug: 0 g/d CICR-NAM (blinded)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (blinded)
Trial: NCT04504708
Drug: ZX-101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
Trial: NCT04839328
Drug: 60mg Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay005 is a small molecule PDE4 inhibitor.
Trial: NCT04839328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos are the same as drugs, but contain no Hemay005.
Trial: NCT06205121
Drug: OATD-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
Trial: NCT06205121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT06371326
Drug: ZT002 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ZT002 by subcutaneous (SC) injection.
Trial: NCT06371326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo by subcutaneous (SC) injection.
Trial: NCT04773678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous (SC) injection.
Trial: NCT06181526
Drug: Aleeto
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.
Trial: NCT06304103
Drug: AND017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer AND017 once per day (QD)
Trial: NCT06345716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
Trial: NCT06532643
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
Trial: NCT04773964
Drug: MET642
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET642 active treatment
Trial: NCT04773964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06676644
Drug: non-adjuvanted
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions